Item 1. Security and Issuer
This Amendment No. 7 to Schedule 13D (this “Amendment”) amends and supplements the initial statement on Schedule 13D filed on June 17, 2021, as amended and supplemented by Amendment No. 1 to Schedule 13D filed on March 21, 2022, Amendment No. 2 to Schedule 13D filed on December 21, 2022, Amendment No. 3 to Schedule 13D filed on January 17, 2023, Amendment No. 4 to Schedule 13D filed on May 30, 2023 (“Amendment No. 4”), Amendment No. 5 to Schedule 13D filed on June 14, 2023 (“Amendment No. 5”) and Amendment No. 6 to Schedule 13D filed on December 5, 2023 (“Amendment No. 6” and, as so amended and supplemented, the “Statement”) by the Reporting Persons relating to the common stock, no par value per share (“Common Stock”) of Vintage Wine Estates, Inc., a Nevada corporation (the “Issuer”).
This Amendment is being filed to report that (i) on December 7, 2023, Bespoke Sponsor Capital LP effected a pro rata in-kind distribution of an aggregate of 333,332 shares of Common Stock to its members for no consideration in a transaction exempt from the requirements of the Securities Act of 1933 (the “Share Distribution”), and (ii) on December 7, 2023, Bespoke Sponsor Capital LP effected a pro rata in-kind distribution of an aggregate of 444,444 warrants to purchase shares of Common Stock to its members for no consideration in a transaction exempt from the requirements of the Securities Act of 1933 (the “Warrant Distribution” and, together with the Share Distribution, the “Distribution”).
Capitalized terms used but not defined in this Amendment have the meanings ascribed to them in the Statement. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Statement.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Statement is hereby amended to add the following:
On December 7, 2023, Bespoke Sponsor Capital LP (the “Sponsor”) effected the Share Distribution of an aggregate of 333,332 shares of Common Stock to its members for no consideration in a transaction exempt from the requirements of the Securities Act of 1933 and (ii) on December 7, 2023, the Sponsor effected the Warrant Distribution of an aggregate of 444,444 warrants to purchase shares of Common Stock to its members for no consideration in a transaction exempt from the requirements of the Securities Act of 1933. As part of the Share Distribution, Mark W.B. Harms received 84,900 shares of Common Stock. As part of the Warrant Distribution, Mark W.B. Harms received 14,351 warrants to purchase shares of Common Stock.
Item 5. Interest in Securities of the Issuer
Item 5(a) and (b) of the Statement is hereby amended and restated as follows:
(a) and (b) The aggregate number of shares of Common Stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the voting thereof, shared power to vote or to direct the voting thereof, sole power to dispose or to direct the disposition thereof, or shared power to dispose or to direct the disposition thereof, are set forth on rows 7 through 11 and row 13 of the cover pages of this Statement and are incorporated herein by this reference thereto.
Item 2(a) of this Statement, which identifies the Reporting Persons, the Major Investors and the Specified Investors and discloses the voting provisions of the Investor Rights Agreement and the Voting Agreement, is incorporated herein by this reference thereto.
On November 22, 2023, the Sponsor and the Proxy Agreement Parties entered into the Irrevocable Proxy Agreement, pursuant to which the Proxy Agreement Parties granted voting power, but not dispositive power, to the Sponsor over the shares of Common Stock held by them. The Irrevocable Proxy Agreement appoints the Sponsor as the irrevocably proxy to vote each share of Common Stock held by each of the Proxy Agreement Parties, including shares of Common Stock that are presently owned or that may be acquired in the future, at each annual or special meeting of shareholders of the Company until and including the Company’s annual meeting of shareholders to be held in 2028. The Irrevocable Proxy Agreement confers authority to vote such shares of Common Stock with respect to any and all matters presented at a meeting of the Company’s shareholders except for certain matters pertaining to (i) the issuance of equity by the Company or adoption of any equity plan by the Company, (b) certain business combination transactions to which the Company is a party, (iii) transactions in which affiliates of the Company have an interest that is different from, or in addition to, the interests of the Company’s shareholders generally, (iv) certain amendments to the Company’s articles of incorporation or bylaws and (v) any matter as to which a Proxy Agreement Party is advised in writing by a nationally recognized law firm that the failure to exercise independent judgment would be a breach of any law, exchange listing requirement, fiduciary duty or contract.
38